ATE521893T1 - P66-shc als prädiktiver marker bei der krebsbehandlung - Google Patents

P66-shc als prädiktiver marker bei der krebsbehandlung

Info

Publication number
ATE521893T1
ATE521893T1 AT06837361T AT06837361T ATE521893T1 AT E521893 T1 ATE521893 T1 AT E521893T1 AT 06837361 T AT06837361 T AT 06837361T AT 06837361 T AT06837361 T AT 06837361T AT E521893 T1 ATE521893 T1 AT E521893T1
Authority
AT
Austria
Prior art keywords
shc
cancer treatment
predictive marker
individual
amount
Prior art date
Application number
AT06837361T
Other languages
English (en)
Inventor
A Frackelton
Original Assignee
Roger Williams Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roger Williams Hospital filed Critical Roger Williams Hospital
Application granted granted Critical
Publication of ATE521893T1 publication Critical patent/ATE521893T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06837361T 2005-11-11 2006-11-10 P66-shc als prädiktiver marker bei der krebsbehandlung ATE521893T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73572905P 2005-11-11 2005-11-11
US84378806P 2006-09-12 2006-09-12
PCT/US2006/043852 WO2007058965A1 (en) 2005-11-11 2006-11-10 P66-shc as predictive marker in cancer treatment

Publications (1)

Publication Number Publication Date
ATE521893T1 true ATE521893T1 (de) 2011-09-15

Family

ID=37761924

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06837361T ATE521893T1 (de) 2005-11-11 2006-11-10 P66-shc als prädiktiver marker bei der krebsbehandlung

Country Status (7)

Country Link
US (1) US20080299590A1 (de)
EP (1) EP1946117B1 (de)
JP (1) JP2009516167A (de)
AT (1) ATE521893T1 (de)
AU (1) AU2006315651A1 (de)
CA (1) CA2627535A1 (de)
WO (1) WO2007058965A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910314B2 (en) 2002-03-01 2011-03-22 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950703003A (ko) * 1993-06-30 1995-08-23 비토리노 페라리오 미토게네시스 및 모토게네시스의 펩타이드 억제제(peptide inhibitors of mitogenesis and motogenesis)
JP3442784B2 (ja) * 1993-11-23 2003-09-02 ジェネンテク，インコーポレイテッド キナーゼ受容体活性化検定法
US6673914B1 (en) * 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
US6492138B1 (en) * 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
KR20080023768A (ko) * 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
MXPA03003011A (es) * 2000-10-05 2003-07-14 George Q Daley Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
WO2003051917A2 (en) * 2001-12-18 2003-06-26 Endocube Sas Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
US7910314B2 (en) * 2002-03-01 2011-03-22 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
US20040209809A1 (en) * 2003-02-19 2004-10-21 Caroline Saucier Shc modulation and uses thereof
EP1984742A1 (de) * 2006-01-20 2008-10-29 Catalyst Oncology, LP Verfahren zur vorhersage des wiederauftretens gastrointestinaler und anderer krebserkrankungen unter verwendung des shc-proteins

Also Published As

Publication number Publication date
CA2627535A1 (en) 2007-05-24
EP1946117A1 (de) 2008-07-23
JP2009516167A (ja) 2009-04-16
US20080299590A1 (en) 2008-12-04
WO2007058965A9 (en) 2007-07-19
AU2006315651A1 (en) 2007-05-24
WO2007058965A1 (en) 2007-05-24
EP1946117B1 (de) 2011-08-24

Similar Documents

Publication Publication Date Title
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
WO2008138578A3 (en) Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007072225A3 (en) Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
ATE539170T1 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
WO2004071572A3 (en) Gene expression markers for response to egfr inhibitor drugs
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
CL2008001517A1 (es) Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga.
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
DE602006012816D1 (de) Tifizierung von zellulären folat vitamin rezeptoren
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
EP1718767A4 (de) Zusammensetzungen und verfahren zur charakterisierung, regulierung, diagnose und behandlung von krebs
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
ATE501267T1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
WO2006134390A3 (en) Method for diagnosing neurodegenerative disease
WO2009055823A3 (en) Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
ATE525484T1 (de) Slco1b3-genotyp
WO2005048818A3 (en) Methods of diagnosing renal disease
WO2007061922A3 (en) Methods to predict and prevent resistance to taxoid compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties